EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Aikaterini Panopoulou iD, David A Cairns iD, Amy Holroyd, Isabel Nichols, Nikita Cray, Charlotte Pawlyn iD, Gordon Cook iD, Mark Drayson, Kevin Boyd, Faith E Davies, Matthew Jenner iD, Gareth J Morgan und 4 weitere

Blood · 2023

DOI: 10.1182/blood.2022018339 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood, 2023. Verfasst von Aikaterini Panopoulou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in patients in the National Cancer Research Institute Myeloma XI (MyXI) trial. Patients in the MyXI trial randomized to Len maintenance or observation after ASCT were genetically profiled for t(4;14), t(14;16), t(14;20), del(1p), gain(1q), and del(17p) and co-occurrence of risk markers was computed. Progression-free survival (PFS), subsequent progression (PFS2), and overall survival (OS) were calculated from maintenance randomization, and groups were compared using Cox proportional hazards regression. Of 556 patients, 17% with double-hit multiple myeloma (MM) (≥2 risk markers), 32% with single-hit (1 risk marker), and 51% without risk markers were analyzed. Single-hit MM derived the highest PFS benefit from Len maintenance, specifically, isolated del(1p), del(17p), and t(4;14), with ∼40-fold, 10-fold, and sevenfold reduced risk of progression or death (PFS), respectively, compared with observation. This benefit translated into improved PFS2 and OS for this group of patients compared with observation; median PFS was 10.9 vs 57.3 months for observation vs Len maintenance. Patients with isolated gain(1q) derived no benefit, and double-hit MM limited benefit (regardless or risk lesions involved) from Len maintenance. Extended genetic profiling identifies patients deriving exceptional benefit from Len maintenance and should be considered for newly diagnosed patients to support management discussions along their treatment pathway. This trial was registered at www.isrctn.com/ISRCTN49407852 as # ISRCTN49407852.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationHumansLenalidomideStem Cell TransplantationPrognosisProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsTransplantation, AutologousDexamethasone

Substanzen

LenalidomideDexamethasone

Autor:innen und Institutionen

  • Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
  • Department of Haematology, Royal Marsden Hospital, London, United Kingdom.
  • Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom.
  • Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Perlmutter Cancer Center, NYU Langone Health, New York, NY.

ORCID-Profile: Aikaterini Panopoulou, David A Cairns, Charlotte Pawlyn, Gordon Cook, Matthew Jenner, Martin F Kaiser

Förderung

  • Cancer Research UK

Zitieren

APA

Panopoulou, A., Cairns, D. A., Holroyd, A., Nichols, I., Cray, N., Pawlyn, C., Cook, G., Drayson, M., Boyd, K., Davies, F. E., Jenner, M., Morgan, G. J., Owen, R., Houlston, R., Jackson, G., & Kaiser, M. F. (2023). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. https://doi.org/10.1182/blood.2022018339

Vancouver

Panopoulou A, Cairns DA, Holroyd A, Nichols I, Cray N, Pawlyn C, et al. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 2023. doi:10.1182/blood.2022018339

BibTeX
@article{Panopoulou2023,
  author = {Panopoulou, Aikaterini and Cairns, David A and Holroyd, Amy and Nichols, Isabel and Cray, Nikita and Pawlyn, Charlotte and Cook, Gordon and Drayson, Mark and Boyd, Kevin and Davies, Faith E and Jenner, Matthew and Morgan, Gareth J and Owen, Roger and Houlston, Richard and Jackson, Graham and Kaiser, Martin F},
  title = {Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018339}
}
Kostenlos starten →